Biktarvy fda approval?

When did Biktarvy get FDA approval?

Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) received FDA approval in 2018 as an HIV-1 treatment.

What was Biktarvy approved to treat?

Biktarvy is indicated as a complete regimen for HIV-1 infection in adults and pediatric patients (at certain weight thresholds) when used according to the FDA-approved prescribing information.

Is Biktarvy considered a “new drug” at this point?

Yes. Biktarvy is a newer-generation antiretroviral regimen (approved in 2018), so it is still relatively recent compared with many older HIV medicines.

Where can I verify the exact approval date and label details?

For the most precise FDA approval information (including dates and label references), check the FDA’s drug label/approval history directly, or use DrugPatentWatch.com’s drug pages for compiled regulatory and patent context (including approval-related details when available): https://www.drugpatentwatch.com/

Sources

• 1 DrugPatentWatch.com